QI
XLRN

QS Investors’s Acceleron Pharma XLRN Stock Holding History

QS Investors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,700
Closed -$601K – 1263
2020
Q4 		$601K Hold
4,700
– – 0.01% 700
2020
Q3 		$529K Sell
4,700
-16,240
-78% -$1.62M 0.01% 666
2020
Q2 		$2M Hold
20,940
– – 0.03% 493
2020
Q1 		$1.88M Buy
20,940
+17,840
+575% +$1.39M 0.03% 438
2019
Q4 		$164K Sell
3,100
-2,400
-44% -$109K ﹤0.01% 1233
2019
Q3 		$218K Hold
5,500
– – ﹤0.01% 1185
2019
Q2 		$226K Buy
+5,500
New +$228K ﹤0.01% 1190

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

QS Investors's XLRN Position: Q1 2021 in Review

QS Investors sold out of Acceleron Pharma (XLRN) in Q1 2021, closing a stake of 4,700 shares — an estimated $601K sold.

QS Investors first reported a position in XLRN in Q2 2019 and held it in 7 quarters. The position peaked at $2M in Q2 2020. 256 funds tracked by Wall St. Rank hold XLRN as of Q1 2021.

  • QS Investors reported no remaining Acceleron Pharma position as of Q1 2021 after selling out during the quarter.
  • QS Investors sold 4,700 Acceleron Pharma shares in Q1 2021, an estimated $601K.
  • QS Investors first reported a position in Acceleron Pharma in Q2 2019 and held it in 7 quarters.
  • QS Investors's Acceleron Pharma position peaked at $2M in Q2 2020.
  • 256 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2021.

Based on QS Investors's 13F filing for Q1 2021, filed 13 May 2021.